FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2883590988> ?p ?o ?g. }

• W2883590988 endingPage "1460" @default.
• W2883590988 startingPage "1457" @default.
• W2883590988 abstract "Serum ceramides have emerged as potential biomarkers of insulin resistance, diabetes, and heart disease. In this issue of Diabetes , Lemaitre et al. (1) report the largest longitudinal study to date correlating sphingolipids with insulin resistance, profiling a cohort of 2,086 American Indians at high risk for diabetes. With the analytical power that derives from profiling such a large number of samples obtained at two visits, 5 years apart, the data from the Strong Heart Family Study (SHFS) revealed that several ceramide species correlated with hyperinsulinemia and the HOMA of insulin resistance (HOMA-IR) in this at-risk population. Here, we summarize these results in the context of other preclinical and clinical studies investigating roles for ceramides as drivers of cardiometabolic dysfunction.Ceramides are central intermediates in the biosynthetic pathway that produces the large family of sphingolipids, which includes more than 4,000 distinct molecular entities. Much of the complexity in the cellular sphingolipid pool derives from the large number of acyl chains that can be incorporated into the ceramide scaffold. Over the past 20 years, a large number of studies in preclinical models suggest that ceramides may be among the most pathogenic nutrient metabolites that accumulate in obesity, linking overnutrition to insulin resistance and its sequelae of comorbidities. In cultured cells or isolated tissues, ceramides inhibit insulin signaling and action and inhibit lipid oxidation (2). In rodents, numerous ceramide-lowering interventions have been shown to improve insulin sensitivity and ameliorate diabetes and cardiovascular pathologies (2). Because of these data, a handful of companies have started to develop ceramide-reducing interventions in hopes of producing insulin-sensitizing therapeutics.Despite the strongly consistent findings obtained in preclinical models, the role of ceramides in human cardiometabolic pathologies has been controversial. The debate stems largely from discordance in …" @default.
• W2883590988 created "2018-08-03" @default.
• W2883590988 creator A5011083228 @default.
• W2883590988 creator A5030757026 @default.
• W2883590988 date "2018-07-13" @default.
• W2883590988 modified "2023-10-11" @default.
• W2883590988 title "Strong Heart, Low Ceramides" @default.
• W2883590988 cites W1522100973 @default.
• W2883590988 cites W1561695121 @default.
• W2883590988 cites W1966609204 @default.
• W2883590988 cites W1980825418 @default.
• W2883590988 cites W2020740038 @default.
• W2883590988 cites W2067132639 @default.
• W2883590988 cites W2072328795 @default.
• W2883590988 cites W2086410640 @default.
• W2883590988 cites W2100198908 @default.
• W2883590988 cites W2133396278 @default.
• W2883590988 cites W2140277745 @default.
• W2883590988 cites W2147382256 @default.
• W2883590988 cites W2147944809 @default.
• W2883590988 cites W2282032965 @default.
• W2883590988 cites W2300039704 @default.
• W2883590988 cites W2301676523 @default.
• W2883590988 cites W2344273352 @default.
• W2883590988 cites W2527947512 @default.
• W2883590988 cites W2537881633 @default.
• W2883590988 cites W2548393767 @default.
• W2883590988 cites W2593053867 @default.
• W2883590988 cites W2619938137 @default.
• W2883590988 cites W2625347005 @default.
• W2883590988 cites W2781794019 @default.
• W2883590988 cites W2794512033 @default.
• W2883590988 cites W2794877394 @default.
• W2883590988 cites W4242539867 @default.
• W2883590988 doi "https://doi.org/10.2337/dbi18-0018" @default.
• W2883590988 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6054437" @default.
• W2883590988 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30030288" @default.
• W2883590988 hasPublicationYear "2018" @default.
• W2883590988 type Work @default.
• W2883590988 sameAs 2883590988 @default.
• W2883590988 citedByCount "14" @default.
• W2883590988 countsByYear W28835909882019 @default.
• W2883590988 countsByYear W28835909882020 @default.
• W2883590988 countsByYear W28835909882021 @default.
• W2883590988 countsByYear W28835909882023 @default.
• W2883590988 crossrefType "journal-article" @default.
• W2883590988 hasAuthorship W2883590988A5011083228 @default.
• W2883590988 hasAuthorship W2883590988A5030757026 @default.
• W2883590988 hasBestOaLocation W28835909881 @default.
• W2883590988 hasConcept C126322002 @default.
• W2883590988 hasConcept C164705383 @default.
• W2883590988 hasConcept C71924100 @default.
• W2883590988 hasConceptScore W2883590988C126322002 @default.
• W2883590988 hasConceptScore W2883590988C164705383 @default.
• W2883590988 hasConceptScore W2883590988C71924100 @default.
• W2883590988 hasFunder F4320337357 @default.
• W2883590988 hasIssue "8" @default.
• W2883590988 hasLocation W28835909881 @default.
• W2883590988 hasLocation W28835909882 @default.
• W2883590988 hasLocation W28835909883 @default.
• W2883590988 hasLocation W28835909884 @default.
• W2883590988 hasOpenAccess W2883590988 @default.
• W2883590988 hasPrimaryLocation W28835909881 @default.
• W2883590988 hasRelatedWork W1531601525 @default.
• W2883590988 hasRelatedWork W2748952813 @default.
• W2883590988 hasRelatedWork W2758277628 @default.
• W2883590988 hasRelatedWork W2899084033 @default.
• W2883590988 hasRelatedWork W2935909890 @default.
• W2883590988 hasRelatedWork W2948807893 @default.
• W2883590988 hasRelatedWork W3173606202 @default.
• W2883590988 hasRelatedWork W3183948672 @default.
• W2883590988 hasRelatedWork W2778153218 @default.
• W2883590988 hasRelatedWork W3110381201 @default.
• W2883590988 hasVolume "67" @default.
• W2883590988 isParatext "false" @default.
• W2883590988 isRetracted "false" @default.
• W2883590988 magId "2883590988" @default.
• W2883590988 workType "article" @default.